Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use

A kind of use, alcohol technology, applied in the field of use of Mavogulan in reducing alcohol use or in preventing re-use of alcohol, can solve the problems that have not been further developed

Pending Publication Date: 2020-03-17
NOVARTIS AG
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, neither MTEP nor MPEP has been further developed due to their shortcomings as therapeutic agents (Keck et al., 2013, Psychopharmacology, 229(2):253-65): for example, MTEP was shown to potently inhibit cytochrome P450 1A2 and rapid metabolism (Smith et al. 2004, Bioorg Med Chem Lett [Bioorganic and Medicinal Chemistry Letters] 14:5481-5484) and, for example, MPEP demonstrated off-target effects on NMDA receptors, monoamine oxidase and norepinephrine transporter (Cosford et al., J.Med.Chem. [Journal of Medicinal Chemistry], 2003, 46(2), pp. 204-206; O'Leary et al., 2000, Br J Pharmacol [British Journal of Pharmacology] 131:1429- 1437; Heidbreder et al., 2003, Synapse 50:269-276; Lea and Faden, 2006 CNS Drug Rev 12:149-166)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
  • Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
  • Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0197] Example 1: Mavogulan or a pharmaceutically acceptable salt thereof for use in reducing alcohol use in patients with alcohol use disorder.

Embodiment 2

[0198] Example 2: Mavogulan or a pharmaceutically acceptable salt thereof is used in preventing alcohol use disorder patients from reusing alcohol.

Embodiment 3

[0199] Example 3: Mavogulan or a pharmaceutically acceptable salt thereof, for use in promoting alcohol use disorder patients to quit alcohol.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of alcohol use by an alcohol use disorder patient; in preventing relapse into alcohol use by an alcohol use disorder patient; in the promotion of alcohol abstinence by an alcohol use disorder patient; in the treatment of the symptoms of depression or anxiety associated with alcohol usedisorder.

Description

[0001] The present invention relates to the use of mGluR5 antagonists. technical field [0002] The present invention relates to the use of an mGluR5 antagonist called mavoglurant or a pharmaceutically acceptable salt thereof in reducing the use of alcohol by patients with alcohol use disorder; and its use in preventing alcohol use in patients with alcohol use disorder; Use in promoting abstinence from alcohol in patients with alcohol use disorder; use in treating symptoms of depression or anxiety associated with alcohol use disorder. In particular, the present invention relates to the use of Mavogulan or a pharmaceutically acceptable salt thereof in reducing the use of alcohol in patients with alcohol use disorders / preventing alcohol use in patients with alcohol use disorders. Background technique [0003] Alcohol use disorder (AUD) is a complex mental disorder defined with reference to the DSM-5 criteria (ie, according to the Diagnostic and Statistical Manual of Mental Dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/404A61K45/06A61P25/32
CPCA61K45/06A61K31/404A61P25/32A61K2300/00A61K31/403
Inventor R·多尔梅奇F·加斯帕里尼D·约翰斯B·戈麦斯-曼西拉
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com